Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9654540 | 0.83 | CA2 (0.39) | CA12CA9ALDH1A1KMT2AMEN1 | |
| SCHEMBL5324671 | 0.81 | LMNA (0.44) | CA12CA9ALDH1A1KMT2AMEN1 | |
| SCHEMBL157580 | 0.80 | MMP2 (0.38) | MMP2CA12CA9CA14ALDH1A1 | |
| SCHEMBL1377737 | 0.76 | MMP2 (0.43) | MMP2CA12CA9CA14ALDH1A1 | |
| SCHEMBL8394723 | 0.76 | ALDH1A1 (0.44) | CA12CA9ALDH1A1KMT2AMEN1 | |
| SCHEMBL4195761 | 0.75 | PTPN1 (0.41) | ALDH1A1KMT2AMEN1PTPN1GAA | |
| SCHEMBL259737 | 0.74 | MMP2 (0.41) | MMP2CA12CA9CA14ALDH1A1 | |
| SCHEMBL10572140 | 0.73 | STAT3 (0.44) | ALDH1A1KMT2AMEN1GAAENPP1 | |
| SCHEMBL2325755 | 0.73 | STAT3 (0.44) | ALDH1A1KMT2AMEN1GAAENPP1 | |
| SCHEMBL10572152 | 0.73 | STAT3 (0.44) | ALDH1A1KMT2AMEN1GAAENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1256585-B1 | Process for preparing 9-(2-(diethylphosphonomethoxy)ethyl)-adenine | GILEAD SCIENCES INC (US) | 2004-09-29 | — | — | EP | claimed |
| EP-4543859-A1 | 3-(SULPHONYL OR SULFONIMIDOYL)PROP-2-EN-1-YL]-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES | Flindr Therapeutics B.V. (NL) | 2025-04-30 | — | — | EP | disclosed |
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| CN-118488854-A | Self-assembling amphiphilic polymers as anti-COVID-19 agents | 阿列克斯塞尔公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4353732-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023249490-A1 | 3-(SULPHONYL OR SULFONIMIDOYL)PROP-2-EN-1-YL]-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES | IMMAGENE B.V. (NL) | 2023-12-28 | — | — | WO | disclosed |
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | JANSSEN BIOPHARMA, LLC | 2020-12-17 | — | — | US | disclosed |
| US-10745427-B2 | Acyclic antivirals | Janssen Biopharma, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190055273-A1 | ACYCLIC ANTIVIRALS | Janssen Pharmaceuticals, Inc. | 2019-02-21 | — | — | US | disclosed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20050137141-A1 | Prodrug composition | HILFINGER JOHN (US) | 2005-06-23 | — | — | US | disclosed |
| US-RE38333-E1 | Making tenofovir analogs and salts; use as viricides for HIV, retroviruses | GILEAD SCIENCES, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-1301519-A2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES, INC. (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002008241-A2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-6069249-A | CHEMICAL INTERMEDIATES; DETECTION LABELS FOR NUCLEOTIDE PROBES | GILEAD SCIENCES, INC. (US) | 2000-05-30 | — | — | US | disclosed |
| US-5686629-A | CHEMICAL INTERMEDIATES | GILEAD SCIENCES, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5514798-A | REACTION OF CYCLIC CARBONATE WITH PURINE OR PYRIMIDINE BASE IN SOLVENT AND CRYSTALLIZATION | GILEAD SCIENCES, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0550574-A1 | HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992005180-A1 | HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | MMP2 3529/4885CA12 4723/4885CA9 4448/4885 |
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | ENTPD5, ENTPD1, ENTPD2 | MMP2 595/4885CA12 740/4885CA9 349/4885 |
| US-20190055273-A1 | ACYCLIC ANTIVIRALS | PNP, TYMP, DUT | MMP2 3224/4885CA12 4719/4885CA9 4477/4885 |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | PNP, DUT, TYMP | MMP2 3529/4885CA12 4723/4885CA9 4448/4885 |
| US-20050137141-A1 | Prodrug composition | CYP3A5, SLC35B2, SLC1A5 | MMP2 451/4885CA12 2806/4885CA9 1108/4885 |
| US-10745427-B2 | Acyclic antivirals | PNP, DUT, TYMP | MMP2 3529/4885CA12 4723/4885CA9 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.